Navigation Links
Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
Date:11/18/2009

GOTHENBURG, Sweden, November 18 /PRNewswire/ -- Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US phase 2b study (http://www.clinicaltrials.gov) under an IND recently placed into effect by the FDA.

Notes for Editors:

About CIC

Constipation is one of the most common gastrointestinal complaints. Chronic idiopathic constipation is a more severe and disabling disease, which is not effectively managed by current treatment options. More than 4 million Americans have chronic constipation resulting in 9 million physician visits annually and in addition lead to more than 92,000 hospitalizations annually. In a survey study of 557 individuals with chronic constipation, 47% of respondents indicated a lack of satisfaction with treatment (82% citing lack of treatment efficacy as the reason for dissatisfaction).

About A3309

A3309 is a therapeutic alternative with a novel mechanism of action developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). A3309 modulates the re-uptake of bile acids by inhibiting the ileal bile acid transporter. This will result in an increased concentration of bile acids in the colon which, in turn, increase fluid secretion and colonic motility. These physiological responses should provide benefits to patients with chronic constipation and IBS-C without any effects on other parts of the gastrointestinal tract.

About Albireo

Albireo is an independent Swedish biotechnology company focused on the development of novel therapeutic alternatives to fulfill medical needs in the gastrointestinal area. Albireo was spun-out of AstraZeneca in February 2008 and is financed by a syndicate of growth capital firms, including Nomura Phase4 Ventures, TPG growth, TVM Capital and Scottish Widows Investment Partnership. The company has raised $40m in its Series A financing round (http://www.albireopharma.com).

SOURCE Albireo


'/>"/>
SOURCE Albireo
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their ... have been used to remove decayed dental matter, and that teeth were then filled ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between ... relative proportion of young people involved in violence in the United States. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a ... B-595 and B-7569 vinyl label materials received certification for the ... are tested to remain intact and legible, for use on chemical drums shipped by ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The adage ... Flex House, the next project in the company’s esteemed VISION House demonstration project series. ... use exactly the amount of resources they need to live affordably and abundantly without ...
(Date:4/21/2017)... ... 21, 2017 , ... The Hong Kong Polytechnic University (PolyU) launched today the ... education institutions in Hong Kong to support teaching, learning and research. It is also ... of facilities in Hong Kong. , With an area of 620 square metres ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 Global ... drainage devices are tubes used to remove excess liquid ... blood, serum, pus, urine, bile or lymph. Surgical drains ... of surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, ... is prophylactic post-surgery to prevent accumulation of fluid e.g. ...
(Date:4/19/2017)... , April 19, 2017 The Global ... Forecast to 2022 report has covered and analysed the potential ... information on market size, shares and growth factors. The report ... challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology: